Depressive Illness Burden Associated With Complex Polypharmacy in Patients With Bipolar Disorder
- 10 February 2009
- journal article
- research article
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 70 (2), 155-162
- https://doi.org/10.4088/jcp.08m04301
Abstract
Many patients with bipolar disorder receive multi-drug treatment regimens, but the distinguishing profiles of patients who receive complex pharmacologies have not been established. Prescribing patterns of lithium, anticonvulsants, antidepressants, and antipsychotics were examined for 4035 subjects with bipolar disorder (DSM-IV) immediately prior to entering the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Subjects were recruited for participation across 22 centers in the United States between November 1999 and July 2005. The quality receiver operating characteristic (ROC) method was used to develop composite profiles of patients receiving complex regimens (p < .01 for all iterations). Use of 3 or more medications occurred in 40% of subjects, while 18% received 4 or more agents. Quality ROC analyses revealed that subjects had a 64% risk for receiving a complex regimen (≥ 4 medications) if they had (1) ever taken an atypical antipsychotic, (2) ≥ 6 lifetime depressive episodes, (3) attempted suicide, and (4) an annual income ≥ $75,000. Complex polypharmacy was least often associated with lithium, divalproex, or carbamazepine and most often associated with atypical antipsychotics or antidepressants. Contrary to expectations, a history of psychosis, age at onset, bipolar I versus II subtype, history of rapid cycling, prior hospitalizations, current illness state, and history of alcohol or substance use disorders did not significantly alter the risk profiles for receiving complex regimens. Complex polypharmacy involving at least 4 medications occurs in approximately 1 in 5 individuals with bipolar disorder. Use of traditional mood stabilizers is associated with fewer cotherapies. Complex regimens are especially common in patients with substantial depressive illness burden and suicidality, for whom simpler drug regimens may fail to produce acceptable levels of response. clinicaltrials.gov Identifier: NCT00012558Keywords
This publication has 36 references indexed in Scilit:
- The Prospective Course of Rapid-Cycling Bipolar Disorder: Findings From the STEP-BDAmerican Journal of Psychiatry, 2008
- Olanzapine plus carbamazepinev.carbamazepine alone in treating manic episodesThe British Journal of Psychiatry, 2008
- Effectiveness of Adjunctive Antidepressant Treatment for Bipolar DepressionNew England Journal of Medicine, 2007
- Factors Associated With Psychiatric Hospitalization of Individuals Diagnosed With Dementia and Comorbid Bipolar DisorderJournal of Geriatric Psychiatry and Neurology, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- Suicide and Attempted Suicide in Bipolar DisorderThe Journal of Clinical Psychiatry, 2005
- Combination of a Mood Stabilizer With Risperidone or Haloperidol for Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Comparison of Efficacy and SafetyAmerican Journal of Psychiatry, 2002
- Double-Blind, Placebo-Controlled Comparison of Imipramine and Paroxetine in the Treatment of Bipolar DepressionAmerican Journal of Psychiatry, 2001
- Valproate as an Adjunct to Neuroleptic Medication for the Treatment of Acute Episodes of Mania: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter StudyJournal of Clinical Psychopharmacology, 2000
- A Pilot Study of Lithium Carbonate Plus Divalproex Sodium for the Continuation and Maintenance Treatment of Patients With Bipolar I DisorderThe Journal of Clinical Psychiatry, 1997